1 Health Care and 2 Earnings Trades Seeing Bullish Options Flow
In Monday’s Blitz Daily, we’ll take a look at drug developer Novartis after it was on the receiving end of several positive news stories.
Monday saw the bulls take a run at drugmaker Novartis, buying long-dated options in size! The company recently announced the launch of phase three trials of its spinal muscular atrophy drug, Zolgensma, in early August.
The Swiss-based firm also reported promising developments with its Kymriah line of cancer therapeutics. That helped bring buyers back for a massive second dip into the options chain this month.
We’re also seeing lots of interest in two of the biggest names in retail reporting earnings this week, along with some green energy tickers. See for yourself…
Disclaimer & Disclosures The information in this email is intended for informational purposes only and does not guarantee specific results as there is a high degree of risk involved with trading. Also, our traders are real traders and may have financial interests in the companies discussed. Please see our Terms and Conditions for more information.
Post a Comment
Post a Comment